Search

Your search keyword '"Secondo Lastoria"' showing total 9 results
Start Over Author "Secondo Lastoria" Journal annals of oncology
9 results on '"Secondo Lastoria"'

1. 491P Neoadjuvant nivolumab in early stage colorectal cancer

Author

N. Zanaletti, Carlo Vitagliano, P.A. Ascierto, Jérôme Galon, Paolo Delrio, Alfredo Budillon, E. Di Gennaro, A. Avallone, S. De Franciscis, A. De Stefano, I. Boquet, Secondo Lastoria, Susan Costantini, Fabiana Tatangelo, Diana Giannarelli, A. Cassata, Ugo Pace, Francesca Collina, Vincenza Granata, and Aurelie Catteau

Subjects
Oncology, medicine.medical_specialty, business.industry, Colorectal cancer, Internal medicine, medicine, Hematology, Nivolumab, Stage (cooking), business, medicine.disease
Published
2020
Full Text
View/download PDF

2. Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study

Author

Marco Tucci, Riccardo Valdagni, V. Annibale, G. Procopio, Elena Verri, Domenico Bilancia, Piero Marchetti, Giovanni Paganelli, Ettore Seregni, Giovanni Storto, Alessandra Mosca, Eugenio Borsatti, Secondo Lastoria, A. Bagnato, Cora N. Sternberg, Paolo Muto, M. Farsad, S. Panareo, Fabio Monari, and Sergio Baldari

Subjects
medicine.medical_specialty, Oncology, business.industry, medicine, Observational study, Hematology, Radium Ra-223, business, Dermatology
Published
2017
Full Text
View/download PDF

3. A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with mFOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)

Author

F. Perrone, Salvatore Tafuto, Mauro Piccirillo, Guglielmo Nasti, Paolo Delrio, Domenico Bilancia, A. Cassata, Secondo Lastoria, Alfredo Budillon, Lucrezia Silvestro, Alessandro Ottaiano, A. De Stefano, E. Di Gennaro, G. Rosati, Chiara Carlomagno, A. Avallone, Ciro Gallo, Francesco Izzo, Carmela Romano, and F. Bianco

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, business.industry, Colorectal cancer, Phases of clinical research, Hematology, medicine.disease, Internal medicine, medicine, In patient, business, medicine.drug
Published
2017
Full Text
View/download PDF

4. Phase I/II study of valproic acid (VPA) and short-course radiotherapy (SCRT) plus capecitabine (CAP) as preoperative treatment in low-moderate risk rectal cancer (V-shoRT-R3)

Author

Mauro Piccirillo, P. Marone, Alfredo Budillon, Antonella Petrillo, Paolo Muto, Carmela Romano, F. Perrone, Valentina D’Angelo, Biagio Pecori, A. Avallone, E. Cavalacanti, G. Botti, Ugo Pace, F. Bianco, E. Di Gennaro, Paolo Delrio, Secondo Lastoria, Fabiana Tatangelo, Carmine Granata, and A. De Stefano

Subjects
0301 basic medicine, medicine.medical_specialty, Valproic Acid, business.industry, Colorectal cancer, Hematology, medicine.disease, Gastroenterology, Capecitabine, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Phase i ii, Oncology, 030220 oncology & carcinogenesis, Internal medicine, Medicine, business, Short course radiotherapy, medicine.drug, Preoperative treatment
Published
2018
Full Text
View/download PDF

5. Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE)

Author

Paolo Delrio, Lucrezia Silvestro, Guglielmo Nasti, A. Cassata, Secondo Lastoria, Ernesta Cavalcanti, Anna Nappi, Fabiana Tatangelo, Carmela Romano, P.A. Ascierto, A. De Stefano, Alfredo Budillon, Rossana Casaretti, Alessandro Ottaiano, Jérôme Galon, Piera Maiolino, Antonella Petrillo, E. Di Gennaro, A. Avallone, and Diana Giannarelli

Subjects
Oncology, medicine.medical_specialty, Window of opportunity, business.industry, Colorectal cancer, Locally advanced, Hematology, medicine.disease, Internal medicine, Medicine, In patient, Nivolumab, business
Published
2018
Full Text
View/download PDF

6. Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)

Author

Francesco Izzo, Ugo Pace, Salvatore Tafuto, Rossana Casaretti, Lucrezia Silvestro, A. De Stefano, F. Bianco, Guglielmo Nasti, Mauro Piccirillo, A. Cassata, G. Rosati, Chiara Carlomagno, C. Gallo, Carmela Romano, Paolo Delrio, A. Avallone, E. De Gennaro, Domenico Bilancia, Vittorio Albino, Secondo Lastoria, Alfredo Budillon, and Alessandro Ottaiano

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, business.industry, Colorectal cancer, Phases of clinical research, Hematology, medicine.disease, FOLFOX, Internal medicine, medicine, In patient, business, Survival analysis, medicine.drug
Published
2018
Full Text
View/download PDF

7. Optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC): the multicentre, randomized phase 3 study OBELICS

Author

Secondo Lastoria, P. Del Rio, Domenico Bilancia, G. Rosati, Chiara Carlomagno, F. Perrone, A. Avallone, F. Bianco, A. De Stefano, Guglielmo Nasti, A. Cassata, Carmela Romano, Alessandro Ottaiano, Francesco Izzo, Mauro Piccirillo, E. Di Gennaro, Alfredo Budillon, Lucrezia Silvestro, Salvatore Tafuto, and Ciro Gallo

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Bevacizumab, business.industry, Colorectal cancer, Phases of clinical research, Hematology, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, FOLFOX, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, business, medicine.drug
Published
2017
Full Text
View/download PDF

8. A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer (mCRC)

Author

A. Antonio, Guglielmo Nasti, Alfredo Budillon, Corrado Caracò, G. Rosati, Alessandro Ottaiano, Carmela Romano, F. Perrone, Paolo Delrio, Mauro Piccirillo, Domenico Bilancia, A. De Stefano, Secondo Lastoria, E. Di Gennaro, C. Gallo, A. Cassata, Rosario Vincenz Iaffaioli, C. Chiara, F. Bianco, and Francesco Izzo

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, business.industry, Colorectal cancer, Phases of clinical research, Hematology, medicine.disease, FOLFOX, Internal medicine, medicine, business, medicine.drug
Published
2016
Full Text
View/download PDF

9. Neoadjuvant Multidisciplinary Phase II Study (BRANCH) of an Early Bevacizumab Schedule Plus Chemo-Radiation Therapy in Rectal Cancer: Efficacy, Safety, and Biomarkers

Author

Vincenzo Rosario Iaffaioli, Secondo Lastoria, Fabiana Tatangelo, Luigi Aloj, A. Avallone, Paolo Delrio, Antonella Petrillo, Biagio Pecori, Alfredo Budillon, and E. Di Gennaro

Subjects
Tumor Regression Grade, Oncology, medicine.medical_specialty, Bevacizumab, business.industry, medicine.medical_treatment, Phases of clinical research, Hematology, Oxaliplatin, Radiation therapy, Folinic acid, Regimen, Internal medicine, Medicine, business, Raltitrexed, medicine.drug
Abstract

Background In BRANCH study we assess the safety and efficacy of an experimental schedule of early (4 days before) bevacizumab (BEV) added to neoadjuvant chemotherapy (CT) and radiotherapy (RT) in poor-risk locally advanced rectal cancer (pLARC) patients (pts) and explore the potential of circulating endothelial cells (CECs) and tumor lesion glycolysis (TLG) as surrogate markers of pathological response(PR). Patients and methods 46 pts (cT4, cN + , cT3≤ 5 cm from the anal verge and/or positive circumferential margin, M1 resectable) received 3 biweekly courses of oxaliplatin (100 mg/m2)/raltitrexed (2.5 mg/m2) on day 1, and 5-FU (800 mg/m2)/folinic acid (250 mg/m2) on day 2 during pelvic RT (45 Gy). BEV (5 mg/kg) was given biweekly 4 days before beginning of CT/RT for 2 courses. Toxicity was graded with NCI-CTC v.3. PR was defined using Mandard tumor regression grade (TRG). According to the Simon's two-stage design, assuming an hypothesis of a 50% TRG1 (complete tumor regression) (α error = 0.05, β error = 0.20), at least 6/16 TRG1 should be obtained to continue accrual to 46 pts. CECs and TLG were evaluated at baseline (BL) on day 10 and before surgery, by flow cytometry and FDG-PET, respectively. Statistical analysis was by Mann-Whitney test. Results We obtained 23 TRG1 (50%), 14 TRG2 (30%) and 8 TRG3-4 (17%). Grade ¾ neutropenia was the most common adverse event (13/46 pts, 28%). TLG reduction on day 10 vs BL was significantly higher in responders TRG1-2 compared to non-responders TRG3-4 pts (median -72%, range -90% + 31% vs -38%, range -45% + 25%; p Conclusions Current scheme of BEV plus CT and RT appears safe and active, yielding high rate of TRG1 and TRG2 responses in pLARC. Early FDG-PET and CECs evaluation emerged as potential biomarkers for treatment selection to be incorporated in design of future studies with this regimen. CEP and citochine data will be provided at the meeting. Disclosure All authors have declared no conflicts of interest.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results